Reviewing XOMA (NASDAQ:XOMAP) and Benitec Biopharma (NASDAQ:BNTC)

Benitec Biopharma (NASDAQ:BNTC) and XOMA (NASDAQ:XOMAP) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Profitability

This table compares Benitec Biopharma and XOMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
XOMA	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for Benitec Biopharma and XOMA, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1	2	7	0	2.60
XOMA	0	0	0	0	0.00

Benitec Biopharma presently has a consensus price target of $24.80, indicating a potential upside of 81.95%. Given Benitec Biopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Benitec Biopharma is more favorable than XOMA.

Valuation and Earnings

This table compares Benitec Biopharma and XOMA”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92 million	($1.14)	-11.96
XOMA	$7.65 million	N/A	N/A	N/A	N/A

XOMA has higher revenue and earnings than Benitec Biopharma.

Institutional & Insider Ownership

52.2% of Benitec Biopharma shares are owned by institutional investors. 4.8% of Benitec Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Benitec Biopharma beats XOMA on 5 of the 8 factors compared between the two stocks.

About Benitec Biopharma

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

About XOMA

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.